Recent data regarding the role of emerging infectious agents such as the Chikungunya virus (CHIKV) in the pathogenesis of certain rheumatic manifestations will be reviewed. Furthermore, in patients with rheumatic diseases that are being treated with biologic agents, the risk of reactivation of certain viruses like hepatitis B virus (HBV) or varicella zoster virus (VZV-causing herpes zoster in adults), seems to be increased. Newer prophylactic treatment strategies for HBV as well as preventive measures by vaccination for herpes zoster have been suggested and will be reviewed. Moreover, the breakthrough advancements last year by the publication of pivotal trials showing the efficacy of different oral direct antivirals in chronic hepatitis C have opened the road for virus eradication and the hope for cure of HCV-associated rheumatic syndromes. Despite appropriate screening for tuberculosis (TB) a number of rheumatic patients still develop TB during chronic biologic therapy (especially with anti-TNF agents). Recent data regarding the potential role of re-screening during therapy for TB prevention will be presented. The need for vaccination in patients with rheumatic diseases should be emphasized as well as recent data showing the safety and efficacy of the human papilloma virus vaccine in young female patients with juvenile arthritis.
Disclosure of Interest None declared